Under the microscope: How AI can help minimise compliance risks
Posted: 31 October 2022 | Vodori | No comments yet
Dr Joe DiCapite, Vodori Director of Strategy, discusses why he believes a revolution in material review software is coming.
The pharmaceutical industry reviews and approves all its promotional content, as well as some non-promotional content, primarily to reduce the risk of breaking strict compliance rules. This process involves rigorous scientific accuracy checks, as well as subjective decision making about risk management. It can be labour intensive and can divert attention from other high value activities.
Related content from this organisation
Issue
Related topics
Artificial Intelligence, Biopharmaceuticals, Good Manufacturing Practice (GMP), Material Identification, QA/QC, Research & Development (R&D), Technology
